{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:29:01Z","timestamp":1760027341255},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,10]]},"DOI":"10.1093\/bmb\/59.1.69","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T22:55:22Z","timestamp":1027724122000},"page":"69-87","source":"Crossref","is-referenced-by-count":9,"title":["Unstable angina: the first 48 hours and later in-hospital management"],"prefix":"10.1093","volume":"59","author":[{"given":"David E","family":"Newby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith A A","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2001,10]]},"reference":[{"key":"key\n\t\t\t\t20170823062336_B1","doi-asserted-by":"crossref","unstructured":"Fox KAA, Cokkinos DV, Deckers J, Keil U, Maggioni A, Steg G. The ENACT study: a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment. Eur Heart J2000; 21: 1440\u20139","DOI":"10.1053\/euhj.2000.2185"},{"key":"key\n\t\t\t\t20170823062336_B2","doi-asserted-by":"crossref","unstructured":"Collinson J, Flather MD, Fox KA et al. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK). Eur Heart J2000; 21: 1450\u20137","DOI":"10.1053\/euhj.1999.1995"},{"key":"key\n\t\t\t\t20170823062336_B3","doi-asserted-by":"crossref","unstructured":"Hamm CW, Braunwald E. A classification of unstable angina revisited. Circulation2000; 102: 118\u201322","DOI":"10.1161\/01.CIR.102.1.118"},{"key":"key\n\t\t\t\t20170823062336_B4","doi-asserted-by":"crossref","unstructured":"Holmvang L, Clemmensen P, Wagner G, Grande P. Admission standard electrocardiogram for early risk stratification in patients with unstable coronary artery disease not eligible for acute revascularization therapy: a TRIM substudy. ThRombin Inhibition in Myocardial Infarction. Am Heart J1999; 137: 24\u201333","DOI":"10.1016\/S0002-8703(99)70456-4"},{"key":"key\n\t\t\t\t20170823062336_B5","doi-asserted-by":"crossref","unstructured":"Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. N Engl J Med2000; 343: 1139\u201347","DOI":"10.1056\/NEJM200010193431602"},{"key":"key\n\t\t\t\t20170823062336_B6","doi-asserted-by":"crossref","unstructured":"The Fragmin and Fast Revascularisation during InStability in Coronary artery disease (FRISC II) investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet1999; 354: 708\u201315","DOI":"10.1016\/S0140-6736(99)07349-3"},{"key":"key\n\t\t\t\t20170823062336_B7","doi-asserted-by":"crossref","unstructured":"Antman EM, Tanasijevic MJ, Thompson B et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med1996; 335: 1342\u20139","DOI":"10.1056\/NEJM199610313351802"},{"key":"key\n\t\t\t\t20170823062336_B8","doi-asserted-by":"crossref","unstructured":"Hamm CW, Heeschen C, Goldmann B et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med1999; 340: 1623\u20139","DOI":"10.1056\/NEJM199905273402103"},{"key":"key\n\t\t\t\t20170823062336_B9","doi-asserted-by":"crossref","unstructured":"Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet1999; 354: 1757\u201362","DOI":"10.1016\/S0140-6736(99)10285-X"},{"key":"key\n\t\t\t\t20170823062336_B10","doi-asserted-by":"crossref","unstructured":"Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet1997; 349: 462\u20136","DOI":"10.1016\/S0140-6736(96)07591-5"},{"key":"key\n\t\t\t\t20170823062336_B11","doi-asserted-by":"crossref","unstructured":"The Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy \u2013 I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ1994; 308: 81\u2013106","DOI":"10.1136\/bmj.308.6921.81"},{"key":"key\n\t\t\t\t20170823062336_B12","doi-asserted-by":"crossref","unstructured":"Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med1997; 336: 973\u20139","DOI":"10.1056\/NEJM199704033361401"},{"key":"key\n\t\t\t\t20170823062336_B13","doi-asserted-by":"crossref","unstructured":"Lewis HD, Davis JW, Archibald DG et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med1983; 309: 396\u2013403","DOI":"10.1056\/NEJM198308183090703"},{"key":"key\n\t\t\t\t20170823062336_B14","doi-asserted-by":"crossref","unstructured":"Balsano F, Rizzon P, Violi F et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation1990; 82: 17\u201326","DOI":"10.1161\/01.CIR.82.1.17"},{"key":"key\n\t\t\t\t20170823062336_B15","doi-asserted-by":"crossref","unstructured":"The CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet1996; 348: 1329\u201339","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"key\n\t\t\t\t20170823062336_B16","doi-asserted-by":"crossref","unstructured":"The CURE investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med2001; 345: 494\u2013502","DOI":"10.1056\/NEJMoa010746"},{"key":"key\n\t\t\t\t20170823062336_B17","doi-asserted-by":"crossref","unstructured":"The Platelet Receptor inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and symptoms (PRISM-PLUS) study investigators. Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med1998; 338: 1488\u201397","DOI":"10.1056\/NEJM199805213382102"},{"key":"key\n\t\t\t\t20170823062336_B18","doi-asserted-by":"crossref","unstructured":"The Platelet glycoprotein IIb\/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial investigators. Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med1998; 339: 436\u201343","DOI":"10.1056\/NEJM199808133390704"},{"key":"key\n\t\t\t\t20170823062336_B19","doi-asserted-by":"crossref","unstructured":"The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty. N Engl J Med1994; 330: 956\u201361","DOI":"10.1056\/NEJM199404073301402"},{"key":"key\n\t\t\t\t20170823062336_B20","doi-asserted-by":"crossref","unstructured":"The CAPTURE study investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet1997; 349: 1429\u201335","DOI":"10.1016\/S0140-6736(96)10452-9"},{"key":"key\n\t\t\t\t20170823062336_B21","unstructured":"The TARGET Investigators. Do Tirofiban and ReoPro give Similar Efficacy Trial. New Orleans, LA: The American Heart Association, 2000"},{"key":"key\n\t\t\t\t20170823062336_B22","unstructured":"The TACTICS investigators. Treat angina with Aggrastat and determine the Cost of Therapy with Invasive or Conservative Strategies. New Orleans, LA: The American Heart Association, 2000"},{"key":"key\n\t\t\t\t20170823062336_B23","unstructured":"The Global Use of Strategies To Open occluded coronary arteries (GUSTO) IV investigators. GUSTO-IV: Abciximab in Unstable Angina. Amsterdam: The European Society of Cardiology, 2000"},{"key":"key\n\t\t\t\t20170823062336_B24","doi-asserted-by":"crossref","unstructured":"Kong DF, Califf RM, Miller DP et al. Clinical outcomes of therapeutic agents that block the glycoprotein IIb\/IIIa integrin in ischemic heart disease. Circulation1998; 98: 2829\u201335","DOI":"10.1161\/01.CIR.98.25.2829"},{"key":"key\n\t\t\t\t20170823062336_B25","doi-asserted-by":"crossref","unstructured":"Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA1996; 276: 811\u20135","DOI":"10.1001\/jama.276.10.811"},{"key":"key\n\t\t\t\t20170823062336_B26","doi-asserted-by":"crossref","unstructured":"Klein W, BuchWald A, Hillis SE et al for the FRagmin In unstable Coronary artery disease (FRIC) study investigators. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Circulation1997; 96: 61\u20138","DOI":"10.1161\/01.CIR.96.1.61"},{"key":"key\n\t\t\t\t20170823062336_B27","doi-asserted-by":"crossref","unstructured":"Cohen M, Demers C, Gurfinkel EP et al for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events (ESSENCE) study group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med1997; 337: 447\u201352","DOI":"10.1056\/NEJM199708143370702"},{"key":"key\n\t\t\t\t20170823062336_B28","doi-asserted-by":"crossref","unstructured":"Antman EM, McCabe CH, Gurfinkel EP et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation1999; 100: 1593\u2013601","DOI":"10.1161\/01.CIR.100.15.1593"},{"key":"key\n\t\t\t\t20170823062336_B29","doi-asserted-by":"crossref","unstructured":"The FRAXIS Study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction: FRAXIS (FRAXiparine in Ischaemic Syndrome). Eur Heart J1999; 20: 1553\u201362","DOI":"10.1053\/euhj.1999.1879"},{"key":"key\n\t\t\t\t20170823062336_B30","doi-asserted-by":"crossref","unstructured":"Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet2000; 355: 1936\u201342","DOI":"10.1016\/S0140-6736(00)02324-2"},{"key":"key\n\t\t\t\t20170823062336_B31","doi-asserted-by":"crossref","unstructured":"Goodman SG, Cohen M, Bigonzi F et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol2000; 36: 693\u20138","DOI":"10.1016\/S0735-1097(00)00808-1"},{"key":"key\n\t\t\t\t20170823062336_B32","doi-asserted-by":"crossref","unstructured":"The Global Use of Strategies To Open occluded coronary arteries (GUSTO) IIb investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med1996; 335: 775\u201382","DOI":"10.1056\/NEJM199609123351103"},{"key":"key\n\t\t\t\t20170823062336_B33","doi-asserted-by":"crossref","unstructured":"The Organisation to Assess Strategies for Ischemic Syndromes (OASIS-1) investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Circulation1997; 96: 769\u201377","DOI":"10.1161\/01.CIR.96.3.769"},{"key":"key\n\t\t\t\t20170823062336_B34","doi-asserted-by":"crossref","unstructured":"The Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet1999; 353: 429\u201338","DOI":"10.1016\/S0140-6736(98)07332-2"},{"key":"key\n\t\t\t\t20170823062336_B35","doi-asserted-by":"crossref","unstructured":"Greinacher A, Lubenow N. Recombinant hirudin in clinical practice : focus on lepirudin. Circulation2001; 103: 1479\u201384","DOI":"10.1161\/01.CIR.103.10.1479"},{"key":"key\n\t\t\t\t20170823062336_B36","doi-asserted-by":"crossref","unstructured":"Mark DB, Cowper PA, Berkowitz SD et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events. Circulation1998; 97: 1702\u20137","DOI":"10.1161\/01.CIR.97.17.1702"},{"key":"key\n\t\t\t\t20170823062336_B37","doi-asserted-by":"crossref","unstructured":"Stone PH, Gibson RS, Glasser SP et al. Comparison of propranolol, diltiazem and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Circulation1990; 82: 1962\u201372","DOI":"10.1161\/01.CIR.82.6.1962"},{"key":"key\n\t\t\t\t20170823062336_B38","doi-asserted-by":"crossref","unstructured":"Dargie HJ, Ford I, Fox KM. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J1996; 17: 104\u201312","DOI":"10.1093\/oxfordjournals.eurheartj.a014668"},{"key":"key\n\t\t\t\t20170823062336_B39","doi-asserted-by":"crossref","unstructured":"Freemantle N, Cleland J, Young P, Mason J, Harrison J. \u03b2-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ1999; 318: 1730\u20137","DOI":"10.1136\/bmj.318.7200.1730"},{"key":"key\n\t\t\t\t20170823062336_B40","doi-asserted-by":"crossref","unstructured":"Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA1988; 260: 2259\u201363","DOI":"10.1001\/jama.260.15.2259"},{"key":"key\n\t\t\t\t20170823062336_B41","doi-asserted-by":"crossref","unstructured":"Cotter G, Metzkor E, Kaluski E et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet1998; 351: 389\u201393","DOI":"10.1016\/S0140-6736(97)08417-1"},{"key":"key\n\t\t\t\t20170823062336_B42","doi-asserted-by":"crossref","unstructured":"Friedensohn A, Meshulam R, Schlesinger Z. Randomised double-blind comparison of the effects of isosorbide dinitrate retard, verapamil sustained-release, and their combination on myocardial ischaemic episodes. Cardiology1991; 79 (Suppl 2): 31\u201340","DOI":"10.1159\/000174922"},{"key":"key\n\t\t\t\t20170823062336_B43","doi-asserted-by":"crossref","unstructured":"Chrysant SG, Glasser SP, Bittar N et al. Efficacy and safety of extended release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol1993; 72: 1249\u201356","DOI":"10.1016\/0002-9149(93)90292-K"},{"key":"key\n\t\t\t\t20170823062336_B44","doi-asserted-by":"crossref","unstructured":"Lubsen J, Tijssen JG. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine\/metoprolol Trial (HINT). Am J Cardiol1987; 60: 18A\u201325A","DOI":"10.1016\/0002-9149(87)90494-2"},{"key":"key\n\t\t\t\t20170823062336_B45","doi-asserted-by":"crossref","unstructured":"The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial \u2013 DAVIT II). Am J Cardiol1990; 66: 779\u201385","DOI":"10.1016\/0002-9149(90)90351-Z"},{"key":"key\n\t\t\t\t20170823062336_B46","doi-asserted-by":"crossref","unstructured":"The Multicenter Diltiazem Post Infarction Trial (MDPIT) research group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med1988; 319: 385\u201392","DOI":"10.1056\/NEJM198808183190701"},{"key":"key\n\t\t\t\t20170823062336_B47","doi-asserted-by":"crossref","unstructured":"Patel DJ, Purcell HJ, Fox KM. Cardioprotection by opening of the K(ATP) channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical European studies in angina and revascularization. Eur Heart J1999; 20: 51\u20137","DOI":"10.1053\/euhj.1998.1354"},{"key":"key\n\t\t\t\t20170823062336_B48","doi-asserted-by":"crossref","unstructured":"Stone PH, Thompson B, Zaret BL et al. Factors associated with failure of medical therapy in patients with unstable angina and non-Q wave myocardial infarction. A TIMI-IIIB database study. Eur Heart J1999; 20: 1084\u201393","DOI":"10.1053\/euhj.1998.1480"},{"key":"key\n\t\t\t\t20170823062336_B49","doi-asserted-by":"crossref","unstructured":"Antman EM, Cohen M, Bernink PJ et al. The TIMI risk score for unstable angina\/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA2000; 284: 835\u201342","DOI":"10.1001\/jama.284.7.835"},{"key":"key\n\t\t\t\t20170823062336_B50","doi-asserted-by":"crossref","unstructured":"Braunwald E, Antman EM, Beasley JW et al. ACC\/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol2000; 36: 970\u20131062","DOI":"10.1016\/S0735-1097(00)00889-5"},{"key":"key\n\t\t\t\t20170823062336_B51","doi-asserted-by":"crossref","unstructured":"Anderson HV, Cannon CP, Stone PH et al. One year results of the Thrombolysis In Myocardial Infarction (TIMI) IIIB clinical trial: a randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol1995; 26: 1643\u201350","DOI":"10.1016\/0735-1097(95)00404-1"},{"key":"key\n\t\t\t\t20170823062336_B52","doi-asserted-by":"crossref","unstructured":"The RITA-2 Trial Participants. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. Lancet1997; 350: 461\u20138","DOI":"10.1016\/S0140-6736(97)07298-X"},{"key":"key\n\t\t\t\t20170823062336_B53","doi-asserted-by":"crossref","unstructured":"Boden WE, O'Rourke RA, Crawford MH et al. Outcomes in patients with acute non-Q wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy: Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) trial investigators. N Engl J Med1998; 338: 1785\u201392","DOI":"10.1056\/NEJM199806183382501"},{"key":"key\n\t\t\t\t20170823062336_B54","doi-asserted-by":"crossref","unstructured":"Yusuf S, Flather M, Pogue J et al for the OASIS registry investigators. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. Lancet1998; 352: 507\u201314","DOI":"10.1016\/S0140-6736(97)11162-X"},{"key":"key\n\t\t\t\t20170823062336_B55","doi-asserted-by":"crossref","unstructured":"Wallentin L, Lagerqvist B, Husted S, Kontny F, St\u00e5hle, Swahn E for the FRISC II investigators. Outcome at 1 year after invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. Lancet2000; 356: 9\u201316","DOI":"10.1016\/S0140-6736(00)02427-2"},{"key":"key\n\t\t\t\t20170823062336_B56","doi-asserted-by":"crossref","unstructured":"Yusuf S, Zucker D, Peduzzi P et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet1994; 344: 563\u201370","DOI":"10.1016\/S0140-6736(94)91963-1"},{"key":"key\n\t\t\t\t20170823062336_B57","doi-asserted-by":"crossref","unstructured":"Schwartz GG, Olsson AG, Egekowitz MD et al. Effects of atonastatin on early recurrent ischemic events in acute coronary syndromes. JAMA2001; 285:1711\u201318","DOI":"10.1001\/jama.285.13.1711"}],"container-title":["British Medical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/bmb\/article-pdf\/59\/1\/69\/19567508\/69.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T09:33:16Z","timestamp":1583314396000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/bmb\/article\/59\/1\/69\/282086\/Unstable-angina-the-first-48-hours-and-later"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2001,10]]},"published-print":{"date-parts":[[2001,10]]}},"URL":"https:\/\/doi.org\/10.1093\/bmb\/59.1.69","relation":{},"ISSN":["1471-8391","0007-1420"],"issn-type":[{"value":"1471-8391","type":"electronic"},{"value":"0007-1420","type":"print"}],"subject":[],"published":{"date-parts":[[2001,10]]}}}